CRYAB

Across TCGA pan-cancer cohorts, CRYAB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CRYAB data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CRYAB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRYAB expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where CRYAB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.746	0.960	.001	11	view →
PDAC	DFS	Median	II,III,IV	0.496	0.326	.044	3	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.042	3	view →
GBM	OS	Median	All	0.444	0.627	.049	1	view →
CCRCC	DFS	Median	All	0.653	0.846	.047	1	view →
LSCC	DFS	Tertile	III,IV	0.984	0.544	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CRYAB–LUAD (DFS)

Open the LUAD breakdown →